INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...

A randomized clinical trial published in the Journal of Cannabis Research found that a traditional Thai cannabis-based multi-herbal formulation was just as effective as lorazepam in improving sleep ...

Danish drugmaker Novo Nordisk (NOV: N) saw its shares sink more than 16% Monday after its obesity hopeful CagriSema (cagrilintide/semaglutide) failed to show non-inferiority to Eli Lilly’s (NYSE: LLY) ...

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual ...

Novo Nordisk (NVO) crashed roughly 20% today after the pharma giant said its candidate obesity drug CagriSema failed to demonstrate non-inferiority to rival Eli Lilly’s (LLY) tirzepatide in the ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...

Viking Therapeutics Inc. (NASDAQ: VKTX) shares are up on Monday, in reaction to data from Novo Nordisk A/S’ (NYSE: NVO) ...

Eli Lilly shares climb after Novo Nordisk trial miss. CagriSema trails tirzepatide in 84-week weight-loss study results.

Novo Nordisk (NVO) stock drops 15% after CagriSema fails to match Eli Lilly's tirzepatide in an 84-week trial, hitting a ...

Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and ...

Novo Nordisk plunges after CagriSema REDEFINE 4 misses vs. tirzepatide. Click here to read my most recent analysis of NVO ...